Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from in...

Full description

Saved in:
Bibliographic Details
Main Authors: Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Format: Article
Language:English
Published: Gastroenterology Council for Gut and Liver 2025-05-01
Series:Gut and Liver
Subjects:
infliximab; pharmacokinetic model; intravenous; subcutaneous; inflammatory bowel diseases
Online Access:http://gutnliver.org/journal/view.html?doi=10.5009/gnl240503
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items